Controlled release oxycodone compositions
US5656295A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 19, 1996 |
| Grant date | Aug 12, 1997 |
| Priority date | — |
| Expiry date | Mar 19, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/485
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated "q…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.